AR-12286 clinical trials
Also written AR-12286.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses AR-12286 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 2
Aerie Pharmaceuticals (8) · Robert Ritch, MD, LLC. (1) · New York Glaucoma Research Institute (1)
Often tested with
Tested in the same studies.
Latanoprost (1) · PG286 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses AR-12286 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedPhase 2Aerie PharmaceuticalsNCT01699464Written as AR-12286 Ophthalmic Solution 0.7%How we know
- A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or GlaucomaCompletedPhase 2Robert Ritch, MD, LLC.NCT01936389Written as AR-12286How we know
- AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedPhase 2Aerie PharmaceuticalsNCT01474135Written as 0.25% AR-12286 / 0.004% travoprostHow we know
- A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical InterventionStatus unknownPhase 2New York Glaucoma Research InstituteNCT02174991Written as Rho-Kinase Inhibitor (AR-12286)How we know
- AR-12286 in Combination With LatanoprostCompletedPhase 2Aerie PharmaceuticalsNCT01302249Written as AR-12286 Ophthalmic Solution 0.5%How we know
- Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular PressureCompletedPhase 2Aerie PharmaceuticalsNCT01060579Written as AR-12286 0.5% ophthalmic solutionHow we know
- A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)CompletedPhase 2Aerie PharmaceuticalsNCT00902200Written as AR-12286How we know
- 24-hour Efficacy of AR-12286CompletedPhase 2Aerie PharmaceuticalsNCT01330979Written as AR-12286 0.5% Ophthalmic SolutionHow we know
- A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedPhase 2Aerie PharmaceuticalsNCT01789736Written as AR-12286 Ophthalmic Solution 0.5%How we know
- Formulation Comparison in Normal VolunteersCompletedPhase 1Aerie PharmaceuticalsNCT01250197Written as AR-12286How we know